Recognition in research
The signing of the landmark National Cancer Act in 1971 was instrumental in broadening the establishment of multiple new cancer centers designated by the National Cancer Institute (NCI) to conduct cancer research and training. Over the next four years, the federal government would pass new legislation that would expand this Cancer Centers Program across the country in order to “permit an estimated 80 percent of the U.S. population access within a reasonable driving distance” to one of these centers.
Massey is one of 72 cancer centers designated by the NCI, and one of only 56 comprehensive centers. The designation recognizes the center as a leading research institution, demonstrating excellence in cancer research, transdisciplinary science, community outreach and engagement as well as cancer research training and education.
Massey is designated by the NCI as an MU-NCORP institution to lead a statewide clinical trials network that fosters access to cancer research for minority and medically underserved patients. As one of only 14 MU-NCORPs in the country, Massey supports the development and ongoing management of a quality clinical trials program at community practices and health care providers throughout Virginia. Partners have access to innovative cancer trials through membership to all four adult National Clinical Trials Network groups, Children’s Oncology Group and two NCORP Research Bases.
The Association of American Cancer Institutes (AACI) recognizes academic and freestanding cancer centers dedicated to eradicating cancer and promoting health equity. The AACI promotes efforts across various oncology-related areas – including cancer research, government relations, health disparities, clinical research and scientific leadership – to enhance public policy and promote collaboration among members.
Recognition in patient care
For more than a decade, U.S. News & World Report has ranked VCU Medical Center, which includes Massey's oncology patient care, as the number one hospital in the Richmond metro area in its annual “Best Hospitals” rankings, now for the 14th consecutive year. Massey’s cancer care is also recognized as “High Performing” overall, and VCU Medical Center placed among the top two hospitals in Virginia for 2024-2025. U.S. News designates “high-performing” adult specialty areas as close to ranking among the top 50 in the country. Critical procedures and conditions recognized by the highest ranking include:
- Colon cancer surgery
- Gynecological cancer surgery
- Leukemia, lymphoma and myeloma
- Lung cancer surgery
- Prostate cancer surgery
Programs accredited by the Commission on Cancer (CoC) demonstrate a commitment to improving quality of life and survivorship of cancer patients. Accreditation is based on a number of focus areas spanning the cancer continuum including a center’s ability to deliver patient-centered care, demonstrate multidisciplinary approaches, provide access to clinical trials and innovative therapies, improve quality of life and survivorship, as well as offer supportive care services and continued quality improvements in care.
The American College of Radiology (ACR) Designated Comprehensive Breast Imaging Center is achieved through accreditation in all breast imaging modalities including mammography, stereotactic breast biopsy, breast ultrasound and breast MRI.
A Diagnostic Imaging Center of Excellence™ represents excellence of medical imaging facilities – evaluating quality, safety and care – at the highest level within radiology practices.
Facilities named as an ACR Designated Lung Cancer Screening Center™ must have at least one accredited CT unit, including the chest module, and meet screening protocol specifications and personnel qualifications demonstrating excellence in lung cancer screening.
Recognized for exceptional patient care, quality outcomes, innovation and excellence in nursing practice, VCU Medical Center has been re-designated four-consecutive times as a Magnet® hospital by the American Nurses Credentialing Center. The Magnet Recognition Program is the highest national credential for nursing programs and is considered a gold standard.
Accredited by FACT, Massey’s Cellular Immunotherapies and Transplant Program has been recognized for its commitment to equitable patient access and exceptional care across numerous areas including: Adult and Pediatric Autologous and Allogeneic Hematopoietic Progenitor Cellular Therapy, Immune Effector Cellular Therapy, Marrow and Peripheral Blood Cellular Therapy Product Collection and Cellular Therapy Product Processing with Minimal Manipulation. Accreditations are based upon compliance with the most comprehensive standards in the field, verified by rigorous peer-reviewed inspections.
Learn more about Massey's Cellular Immunotherapies and Transplant Program
As a designated Collection and Transplant Center, Massey partners with NMDP Be The Match® to facilitate unrelated transplants, support patients, provide educational opportunities and conduct research.
With more than 50 years of experience, the College of American Pathologists (CAP) is recognized as a global leader in improving the quality of services using established performance standards. The CAP Accreditation enables Massey to foster an environment of continuous improvement that strengthens laboratory excellence to ensure delivery of quality patient care services.
Massey’s Cellular Immunotherapies and Transplant Program has been certified by the following manufacturers to dispense CAR T-Cell therapies – Kite, Novartis, Bristol Myers Squibb and Janssen CAR T-cell therapies. This certification includes implementation and continued compliance with FDA-required Risk Evaluation and Mitigation Strategy processes.
Learn more about Massey's Cellular Immunotherapies and Transplant Program
Programs accredited by the American College of Surgeons’ National Accreditation Program for Breast Centers (NAPBC) reflects a multidisciplinary, integrated approach to comprehensive breast care services from a team of highly qualified health professionals.
In 2023, Massey was named a member of the Caris Precision Oncology Alliance™ (POA) for the center’s use and commitment to leveraging clinical data to improve cancer care and patient outcomes. The POA includes more than 70 other cancer centers and academic institutions.